China Pharma Holdings, Inc. (CPHI) stock
CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
$0.54−0.01 (-1.43%)
Close on Nov 11, 2026Market cap $23.37MP/E –Yield –
China Pharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
China Pharma's profit margin for the twelve months ending Jun 30, 2026 was -114.3%. For fiscal 2025 it was -76.9%, against -104.6% the year before. The highest annual figure on record is 31.5% in fiscal 2010.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -76.9% | +27.7 |
| FY2024 | Dec 31, 2024 | -104.6% | −60.7 |
| FY2023 | Dec 31, 2023 | -43.9% | +5.1 |
| FY2022 | Dec 31, 2022 | -49.0% | −13.8 |
| FY2021 | Dec 31, 2021 | -35.3% | −8.9 |
| FY2020 | Dec 31, 2020 | -26.4% | +163.1 |
| FY2019 | Dec 31, 2019 | -189.5% | −102.3 |
| FY2018 | Dec 31, 2018 | -87.2% | +58.7 |
| FY2017 | Dec 31, 2017 | -145.9% | −86.9 |
| FY2016 | Dec 31, 2016 | -59.0% | +16.7 |
| FY2015 | Dec 31, 2015 | -75.7% | +103.0 |
| FY2014 | Dec 31, 2014 | -178.7% | −117.7 |
| FY2013 | Dec 31, 2013 | -61.0% | −69.5 |
| FY2012 | Dec 31, 2012 | 8.5% | −15.3 |
| FY2011 | Dec 31, 2011 | 23.7% | −7.7 |
| FY2010 | Dec 31, 2010 | 31.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -153.8% | −102.2 |
| Q1 FY2026 | Mar 31, 2026 | -116.2% | −47.1 |
| Q4 FY2025 | Dec 31, 2025 | -99.7% | +8.3 |
| Q3 FY2025 | Sep 30, 2025 | -86.2% | +15.5 |
| Q2 FY2025 | Jun 30, 2025 | -51.5% | +104.0 |
| Q1 FY2025 | Mar 31, 2025 | -69.1% | +0.6 |
| Q4 FY2024 | Dec 31, 2024 | -108.0% | −50.7 |
| Q3 FY2024 | Sep 30, 2024 | -101.6% | −58.5 |
| Q2 FY2024 | Jun 30, 2024 | -155.5% | −101.5 |
| Q1 FY2024 | Mar 31, 2024 | -69.8% | −45.5 |
| Q4 FY2023 | Dec 31, 2023 | -57.3% | −14.0 |
| Q3 FY2023 | Sep 30, 2023 | -43.1% | −2.9 |
| Q2 FY2023 | Jun 30, 2023 | -54.0% | +1.1 |
| Q1 FY2023 | Mar 31, 2023 | -24.3% | +39.9 |
| Q4 FY2022 | Dec 31, 2022 | -43.3% | −9.3 |
| Q3 FY2022 | Sep 30, 2022 | -40.2% | +1.6 |
| Q2 FY2022 | Jun 30, 2022 | -55.1% | −20.9 |
| Q1 FY2022 | Mar 31, 2022 | -64.2% | −31.6 |
| Q4 FY2021 | Dec 31, 2021 | -33.9% | +7.3 |
| Q3 FY2021 | Sep 30, 2021 | -41.8% | +0.3 |
| Q2 FY2021 | Jun 30, 2021 | -34.1% | −34.5 |
| Q1 FY2021 | Mar 31, 2021 | -32.5% | +4.9 |
| Q4 FY2020 | Dec 31, 2020 | -41.2% | +573.7 |
| Q3 FY2020 | Sep 30, 2020 | -42.1% | −12.6 |
| Q2 FY2020 | Jun 30, 2020 | 0.3% | +33.0 |
| Q1 FY2020 | Mar 31, 2020 | -37.5% | −23.2 |
| Q4 FY2019 | Dec 31, 2019 | -614.9% | −380.8 |
| Q3 FY2019 | Sep 30, 2019 | -29.5% | +51.3 |
| Q2 FY2019 | Jun 30, 2019 | -32.6% | −0.9 |
| Q1 FY2019 | Mar 31, 2019 | -14.3% | −6.1 |
| Q4 FY2018 | Dec 31, 2018 | -234.1% | +125.2 |
| Q3 FY2018 | Sep 30, 2018 | -80.8% | −11.3 |
| Q2 FY2018 | Jun 30, 2018 | -31.8% | +46.7 |
| Q1 FY2018 | Mar 31, 2018 | -8.1% | +21.3 |
| Q4 FY2017 | Dec 31, 2017 | -359.4% | −294.3 |
| Q3 FY2017 | Sep 30, 2017 | -69.4% | −13.4 |
| Q2 FY2017 | Jun 30, 2017 | -78.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -29.4% | – |
| Q4 FY2016 | Dec 31, 2016 | -65.1% | – |
| Q3 FY2016 | Sep 30, 2016 | -56.0% | – |
See a number that looks wrong?